| Oct 21 |
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
|
| Oct 9 |
Ionis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge Funds
|
| Oct 8 |
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
|
| Oct 3 |
New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
|
| Oct 2 |
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag
|
| Oct 1 |
Ionis gets U.S. FDA fast track designation for its Alexander disease treatment
|
| Oct 1 |
Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
|
| Sep 12 |
The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly
|
| Sep 11 |
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
|
| Sep 10 |
Ionis announces pricing of $500.3 million public offering
|
